NeuroPace (NPCE) Total Non-Current Liabilities (2020 - 2021)
NeuroPace (NPCE) posted Total Non-Current Liabilities of $60.1 million for Q4 2021, up 1.29% on a QoQ basis from $59.3 million in Q3 2021, and down 3.12% year-over-year from $62.0 million in Q4 2020.
Powered by 
Analysis
NeuroPace (NPCE) Total Non-Current Liabilities (2020 - 2021) Analysis & Trends
NeuroPace has reported Total Non-Current Liabilities for 2 years, with the latest figure at $60.1 million in Q4 2021.
- On a quarterly basis, Total Non-Current Liabilities fell 3.12% year-over-year to $60.1 million in Q4 2021; TTM through Dec 2021 was $60.1 million, a 3.12% decrease from a year earlier, with the FY2021 full-year figure at $60.1 million, down 3.12% from the prior year.
- Total Non-Current Liabilities was $60.1 million for Q4 2021 at NeuroPace, up from $59.3 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $62.0 million in Q4 2020, with the low at $58.1 million in Q2 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn | - |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn | 1.92 Bn |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn | 40.46 Bn |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn | 21.28 Bn |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn | 17.56 Bn |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn | 2.57 Bn |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn | 6.34 Bn |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn | 3.68 Bn |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn | 3.44 Bn |
| 10 | NeuroPace | 493.15 Mn | 441.45 Mn | 18.91 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2021 | 60.06 Mn |
| Sep 30, 2021 | 59.30 Mn |
| Jun 30, 2021 | 58.06 Mn |
| Mar 31, 2021 | 61.85 Mn |
| Dec 31, 2020 | 61.99 Mn |